Dieter Niederacher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/589559/publications.pdf

Version: 2024-02-01

24 papers	2,334 citations	471509 17 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	5243 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
2	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
3	Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 1057-1067.	1.5	1
4	Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancers, 2022, 14, 3292.	3.7	11
5	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
6	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
7	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry Part B - Clinical Cytometry, 2020, 98, 355-367.	1.5	10
8	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research, 2020, 18, 278-286.	3.4	12
9	The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. International Journal of Cancer, 2019, 144, 1761-1763.	5.1	2
10	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Research, 2018, 20, 7.	5.0	78
11	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
12	Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncology, 2017, 3, 1245.	7.1	74
13	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
14	A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 1885.	4.1	37
15	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
16	Predictors of Impaired Postpartum Renal Function in Women after Preeclampsia: Results of a Prospective Single Center Study. Disease Markers, 2016, 2016, 1-8.	1.3	8
17	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
18	Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Review of Molecular Diagnostics, 2016, 16, 147-164.	3.1	89

#	Article	IF	Citations
19	AluY-mediated germline deletion, duplication and somatic stem cell reversion inUBE2Tdefines a new subtype of Fanconi anemia. Human Molecular Genetics, 2015, 24, 5093-5108.	2.9	62
20	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
21	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
22	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
23	Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. International Journal of Cancer, 2001, 92, 309-310.	5.1	25
24	Frequent allele loss on 9p21â€“22 defines a smallest common region in the vicinity of theCDKN2 gene in sporadic breast cancer. , 1996, 17, 14-20.		34